Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025 4:14 PM EDTCatalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook
Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase
FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength
Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 Million
Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025
Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET
CORAL GABLES,... More
